Competitive Intelligence · ADCs · Market, Pipeline & Supply-Chain
Market, competitive, and supply-chain intelligence on the fastest-moving modality in targeted oncology — covering ~20 approved ADCs, 200+ pipeline candidates, landmark deals, and a 2035 forecast. Powered by BIO 360 · HEORvia · Nexigen.
ADCs approved globally
FDA · EMA · PMDA
Candidates in clinical development
Phase I through Phase III
Enhertu partner sales, 2024
Highest-selling ADC globally
Largest ADC acquisition
Pfizer – Seagen, 2023
Forecast market size 2035
Across published analyst models
ADC CDMO market CAGR
$8.9B (2024) → $16.6B (2030)
| Report Code | ARP-ADC-2026-06June 2026 |
|---|---|
| Category | Competitive Intelligence · Market Analysis · Supply Chain |
| Platforms | BIO 360HEORviaNexigen |
| Scope | ~20 approved ADCs · 200+ clinical candidates · 6 landmark deals ($2B–$43B) · ADC CDMO market · HEOR & HTA landscape · 2035 market forecast |
| Key Indications | Breast Cancer (HER2+, HER2-low)Urothelial CancerNSCLCOvarian CancerHematologic Malignancies |
| Methodology | Public analyst and company sources (Roots Analysis, Grand View Research, Technavio, Towards Healthcare) · Company disclosures (Pfizer, AstraZeneca, Daiichi Sankyo, Gilead, AbbVie, Merck, GSK) · FDA/EMA regulatory databases · Not investment advice |
Approved ADCs · Selected Disclosed Assets
| Product (INN) | Target | Company | Approved | Lead Indication | Payload Class |
| Adcetris | CD30 | Pfizer / Takeda | 2011 | Hodgkin lymphoma | Auristatin (MMAE) |
| Kadcyla | HER2 | Roche | 2013 | HER2+ breast cancer | Maytansinoid (DM1) |
| Padcev | Nectin-4 | Astellas / Pfizer | 2019 | Urothelial cancer | Auristatin (MMAE) |
| Enhertu ★ | HER2 | Daiichi Sankyo / AZ | 2019 | HER2+ / HER2-low breast, gastric, NSCLC | Topo-I (deruxtecan) |
| 🔒 Approved ADC 5 | — | Major Pharma | Locked | Details in full report | — |
| 🔒 Approved ADC 6 | — | Major Pharma | Locked | Details in full report | — |
| 14+ more approved, 200+ pipeline assets... | Multiple | Various | All stages | Full details in paid report | — |
Market, competitive, and supply-chain intelligence on the fastest-moving modality in targeted oncology — covering 20+ approved ADCs, 200+ pipeline candidates, landmark deal data, manufacturing dynamics, and a 2035 market forecast.
Article
$79
one-time · single report
Comprehensive
$399
one-time · full deep-dive
Platform
$1,499/mo
team access · all 2,400+ targets
Fill in your details and we'll send the report to your inbox within 48 hours.